Tag Archives: pharmaceutical funding

Pharma Funding & Shrinks for Sale—The Creation of Pre-school Age Bipolar Epidemic

It is difficult to absorb the recent data released by the Agency for Healthcare Research and Quality, AHRQ, and not come to the conclusion that this startling information represents the never-ending harm initiated by the idiotic psychiatric theories of Harvard child psychiatrist, Dr. Joseph Biederman.

In order to fully grasp just how outrageous the data are, one first must remember that the now disgraced and marginalized Biederman is credited with being the ring leader for diagnosing the alleged bipolar disorder in very young children.

American Academy of Pediatrics Promotes Big Pharma Agenda—Labeling and drugging 4-year-olds

4-year-olds on drugs? You betcha. The American Academy of Pediatrics issued new treatment guidelines for “Attention Deficit Hyperactivity Disorder” that say ADHD can be diagnosed in kids as early as age four, and that Ritalin and similar drugs are an appropriate treatment even for children this young. Apparently the “Academy” has no problem with the fact that the US FDA warns drugs like Ritalin can cause hallucinations, mania, heart attack, stroke and sudden death, for a mental ‘disorder’ (ADHD) that is simply based on a checklist of behaviors such as “loses pencils or toys,” “often does not seem to listen,” “is easily distracted by extraneous stimuli,” “fidgets” or “runs about or climbs excessively in situations when it is not appropriate.” And for this, children as young as four should be placed on drugs that the U.S. Drug Enforcement Administration categorizes in the same class of highly addictive drugs as cocaine, morphine and opium.

Right. It should come as no surprise that the chairman of the new ADHD guidelines, Mark Wolraich, MD, is a periodic consultant to Shire Pharmaceuticals, Eli Lilly, Shinogi, and Next Wave Pharmaceuticals, or that the American Academy of Pediatrics (AAP) has receives millions in pharmaceutical funding…

US health agency revises conflict of interest rules

WASHINGTON, Aug 23 (Reuters) – The U.S. National Institutes of Health revised on Tuesday its 16-year-old conflict of interest rules for medical researchers, lowering the amount of money that constitutes a financial conflict and expanding the required disclosures….Concern about the integrity of research in the United States has grown since 2008, when Iowa Republican Sen. Charles Grassley criticized prominent Harvard University psychiatrist Dr. Joseph Biederman and others for failing to fully disclose payments from drug companies.